Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ecopipam - Emalex Biosciences

Next Previous
X
Search
Drug Profile

Ecopipam - Emalex Biosciences

Alternative Names: EBS-101; Ecopipam HCl; Ecopipam Hydrochloride; PSYRX 101; SCH-39166

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough
  • Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
  • Phase II Speech disorders
  • Phase I/II Restless legs syndrome
  • Phase I Cardiovascular disorders
  • No development reported Gambling
  • Discontinued Cocaine-related disorders; Obesity; Schizophrenia

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Lesch-Nyhan-syndrome(In volunteers) in United Kingdom (PO, Controlled release)
  • 27 May 2024 Efficacy data from a phase I trial in Speech disorders released by Emalex Biosciences
  • 22 May 2024 Emalex Biosciences completes a phase I drug-drug interaction trial (In volunteers) in Canada (NCT06194864)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top